Israeli VAT at 18 Percent: Import Taxes and Pricing Implications
Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The Israeli standard value added tax (VAT / Ma’am) rate rose from 17% to 18% with effect from January 1, 2025, and remains the standard rate in 2026. VAT is levied uniformly on the price of domestic transactions or on the price of imported goods, with a taxable base of the customs value plus customs duty, plus purchase tax where applicable. The corporate income tax rate is 23% (2026). Exports and certain transactions are subject to the zero rate. This change directly affects import costs and end-customer pricing models.
- The standard VAT rate is 18% from January 1, 2025; models still using 17% systematically understate tax.
- The VAT base for imports is the customs value plus customs duty plus purchase tax, where applicable.
- Corporate income tax is 23% for 2026.
- Customs duty varies by tariff classification; some categories also attract purchase tax; specific rates are determined by HS code.
- Non-resident businesses operating in Israel must appoint an Israeli resident as tax representative, within 30 days of commencing activity (practical estimate).
- Exports and certain transactions are zero-rated, which allows input tax credit; exempt transactions do not.
2. Legal basis
Unlike the device-specific rules discussed elsewhere in this guide, the tax rules relevant to importers come from general Israeli tax legislation and the 2025 rate adjustment. The table below summarises the instruments and the parameters that matter for pricing models. Regulatory information was verified as of October 29, 2026 against official Israeli legal databases and authoritative public sources; confirm the current position with the Israeli Tax Authority before finalising any pricing decision.
| Legislation | Israeli VAT-related legislation and the 2025 rate adjustment (announcements of the Israeli Tax Authority) |
| Number | The VAT legislation under Israeli tax law; the rate adjustment under the 2025 budget framework |
| Date of publication | The rate adjustment took effect on January 1, 2025 (and continues to apply in 2026) |
| Provisions | Standard rate provisions (18%); taxable base provisions (customs value + customs duty + purchase tax); zero-rating and exemption provisions |
| Practical estimate | Customs duty varies by tariff heading; some categories attract an additional purchase tax; specific rates are determined according to the HS code |
3. Expert insights
A move from 17% to 18% is only one percentage point, but on import costs it lands on a compound tax base: the VAT base includes customs duty, so the higher the duty, the larger the VAT base. This creates an amplification effect of tax on top of tax, which is easy to miss when the change is described as a one-point increase.
A simplified calculation logic illustrates the point (practical estimate): the import-stage tax burden equals the customs duty (per HS code) plus VAT on (customs value + customs duty + purchase tax) at 18%, plus purchase tax where applicable. Companies whose pricing models still run on the old 17% parameter will produce systematic underestimates, and the error is largest precisely in the high-duty categories where margins are already thinner.
Three operating points deserve attention.
Point one: the tariff heading determines the duty. The same product classified under different HS codes can attract duty rates that differ by several percentage points. Classification should be confirmed in advance and kept consistent on the commercial invoice and the customs declaration.
Point two: zero-rating and exemption are not the same thing. Exports and certain transactions are zero-rated, which allows input tax to be credited; exempt transactions do not allow input tax credit. The two produce different cash flow outcomes, and confusing them distorts working capital planning.
Point three: non-resident enterprises must appoint a tax representative. A foreign entity doing business in Israel must appoint an Israeli resident as its tax representative to handle VAT matters, and must complete this within 30 days of commencing activity (practical estimate, in accordance with Israeli tax law requirements).
On the pricing side, the practical effect of the compound base is that duty accuracy and rate accuracy are two different levers. A pricing model that is correct at 18% still misstates the tax if the HS classification is wrong, because the duty element of the base feeds directly into the VAT calculation. Classification, duty rate and VAT rate therefore have to be treated as one linked set of parameters, updated together whenever any one of them changes, rather than as three independent cells in a spreadsheet.
Input tax handling also deserves a note in cash flow planning. Where inputs are creditable, VAT paid at import is recovered through the filing cycle rather than absorbed into cost; where a transaction is exempt, the same amount becomes a permanent cost of that transaction. Distributors and importers should therefore agree early who carries the VAT at each stage of the chain, because the accounting outcome differs between the two treatments even for identical amounts.
4. Practical recommendations
- Update the rate parameters in pricing models. Enter 18% in every calculation dated 2025 or later, and check whether historical models still contain 17%.
- Confirm the HS code early. Keep the classification conclusion consistent with the commercial invoice and the customs declaration to avoid clearance disputes.
- Put the tax representative arrangement in place. Where there is business activity in Israel, appoint a tax representative as required by tax law and complete registration on time.
- Divide tax responsibilities from the IRH. The IRH handles registration and vigilance; the tax representative handles tax. Separate the two roles in the agreements.
5. Verification checklist
- □ The VAT rate in pricing models has been updated to 18% (effective January 1, 2025)
- □ The taxable base is calculated as customs value + customs duty + purchase tax
- □ The HS code has been determined and matches the commercial invoice and customs declaration
- □ Corporate income tax of 23% is reflected in financial modelling (2026)
- □ The tax representative arrangement has been confirmed (practical estimate)
- □ The boundary between the IRH’s and the tax representative’s responsibilities is separately agreed in the contracts
How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Israeli market. Our team coordinates local importer arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us